Michael J. Seminerio

1.0k total citations
44 papers, 777 citations indexed

About

Michael J. Seminerio is a scholar working on Psychiatry and Mental health, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Michael J. Seminerio has authored 44 papers receiving a total of 777 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Psychiatry and Mental health, 16 papers in Molecular Biology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Michael J. Seminerio's work include Migraine and Headache Studies (21 papers), Pharmacological Receptor Mechanisms and Effects (15 papers) and Receptor Mechanisms and Signaling (14 papers). Michael J. Seminerio is often cited by papers focused on Migraine and Headache Studies (21 papers), Pharmacological Receptor Mechanisms and Effects (15 papers) and Receptor Mechanisms and Signaling (14 papers). Michael J. Seminerio collaborates with scholars based in United States, Germany and Belgium. Michael J. Seminerio's co-authors include Rae R. Matsumoto, Matthew J. Robson, Joshua M. Cohen, Christopher R. McCurdy, Meenal Elliott, Stephen D. Silberstein, Christophe Mésangeau, Ronghua Yang, Zaza Katsarava and Sait Ashina and has published in prestigious journals such as Neurology, Clinical Cancer Research and Journal of neurosurgery.

In The Last Decade

Michael J. Seminerio

42 papers receiving 765 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael J. Seminerio United States	18	299	277	215	184	112	44	777
Hamed Sadeghipour Iran	14	125 0.4×	145 0.5×	233 1.1×	71 0.4×	100 0.9×	30	644
Alan W.C. Yuen United Kingdom	18	148 0.5×	909 3.3×	347 1.6×	46 0.3×	227 2.0×	28	1.4k
Rolf Axelsson Sweden	14	237 0.8×	281 1.0×	233 1.1×	16 0.1×	107 1.0×	31	780
Gilly Wolf Israel	16	150 0.5×	87 0.3×	303 1.4×	25 0.1×	366 3.3×	22	771
Julia Aram United Kingdom	10	326 1.1×	131 0.5×	538 2.5×	56 0.3×	89 0.8×	13	853
Zhenxiang Pan China	9	141 0.5×	59 0.2×	147 0.7×	19 0.1×	98 0.9×	17	725
Yi-Chyan Chen Taiwan	15	122 0.4×	78 0.3×	165 0.8×	102 0.6×	70 0.6×	26	560
Ryan Koesterer United States	8	279 0.9×	56 0.2×	182 0.8×	223 1.2×	82 0.7×	12	827
Matilde Capi Italy	14	156 0.5×	323 1.2×	26 0.1×	139 0.8×	134 1.2×	26	563
Élodie Bouaziz-Amar France	16	221 0.7×	194 0.7×	120 0.6×	27 0.1×	403 3.6×	52	727

Countries citing papers authored by Michael J. Seminerio

Since Specialization

Citations

This map shows the geographic impact of Michael J. Seminerio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael J. Seminerio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael J. Seminerio more than expected).

Fields of papers citing papers by Michael J. Seminerio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael J. Seminerio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael J. Seminerio. The network helps show where Michael J. Seminerio may publish in the future.

Co-authorship network of co-authors of Michael J. Seminerio

This figure shows the co-authorship network connecting the top 25 collaborators of Michael J. Seminerio. A scholar is included among the top collaborators of Michael J. Seminerio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael J. Seminerio. Michael J. Seminerio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Niu, Zhongzheng, et al.. (2025). US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review. Advances in Therapy. 42(2). 1207–1221. 1 indexed citations

Buse, Dawn C., et al.. (2024). Real-world Impact of Fremanezumab on Migraine-Related Health Care Resource Utilization in Patients with Comorbidities, Acute Medication Overuse, and/or Unsatisfactory Prior Migraine Preventive Response. Pain and Therapy. 13(3). 511–532. 1 indexed citations

Lantéri‐Minet, Michel, Élizabeth Leroux, Zaza Katsarava, et al.. (2024). Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO-I) study. The Journal of Headache and Pain. 25(1). 134–134. 5 indexed citations

Driessen, Maurice T., et al.. (2022). Reductions in Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab: Results of a Long-term US Claims Database Analysis (P12-2.002). Neurology. 98(18_supplement). 1 indexed citations

Driessen, Maurice T., Joshua M. Cohen, Oscar Patterson‐Lomba, et al.. (2022). Real-world effectiveness of fremanezumab in migraine patients initiating treatment in the United States: results from a retrospective chart study. The Journal of Headache and Pain. 23(1). 47–47. 13 indexed citations

Drießen, Martin, Oscar Patterson‐Lomba, Fan Mu, et al.. (2022). POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting. Value in Health. 25(1). S23–S23.

Seminerio, Michael J., Krishna Tangirala, Rinat Ariely, et al.. (2021). US Real-world Migraine-related Health Care Resource Utilization and Costs for Patients Initiating Fremanezumab (4289). Neurology. 96(15_supplement). 1 indexed citations

Lipton, Richard B., Joshua M. Cohen, Maja Galić, et al.. (2021). Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache The Journal of Head and Face Pain. 61(4). 662–672. 33 indexed citations

Silberstein, Stephen D., Joshua M. Cohen, Sanjay Gandhi, et al.. (2020). Adverse Event Profiles of Therapies that Target the Calcitonin Gene-Related Peptide (CGRP) Pathway, During the First Six Months After Launch: A Real-world Data Analysis Using the FDA Adverse Events Reporting System (FAERS) (4315). Neurology. 94(15_supplement). 3 indexed citations

10.

Lipton, Richard B., Joshua M. Cohen, Kristen Bibeau, et al.. (2020). Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM Study. Headache The Journal of Head and Face Pain. 60(10). 2444–2453. 15 indexed citations

11.

Intagliata, Sebastiano, Abhisheak Sharma, Tamara I. King, et al.. (2020). Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo. The AAPS Journal. 22(5). 94–94. 38 indexed citations

12.

House, Larry, Michael J. Seminerio, Snezana Mirkov, et al.. (2017). Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 48(10). 973–983. 5 indexed citations

13.

Wu, Kehua, Larry House, Jacqueline Ramı́rez, Michael J. Seminerio, & Mark J. Ratain. (2013). Evaluation of Utility of Pharmacokinetic Studies in Phase I Trials of Two Oncology Drugs. Clinical Cancer Research. 19(21). 6039–6043. 5 indexed citations

14.

Stavitskaya, Lidiya, et al.. (2013). Effect of ring-constrained phenylpropyloxyethylamines on sigma receptors. Bioorganic & Medicinal Chemistry. 21(17). 4923–4927. 3 indexed citations

15.

Robson, Matthew J., Michael J. Seminerio, Christopher R. McCurdy, Andrew Coop, & Rae R. Matsumoto. (2013). σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacological Reports. 65(2). 343–349. 11 indexed citations

16.

Seminerio, Michael J. & Mark J. Ratain. (2013). Are Drug Labels Static or Dynamic?. Clinical Pharmacology & Therapeutics. 94(3). 302–304. 7 indexed citations

17.

Behensky, Adam A., et al.. (2012). In Vitro Evaluation of Guanidine Analogs as Sigma Receptor Ligands for Potential Anti-Stroke Therapeutics. Journal of Pharmacology and Experimental Therapeutics. 344(1). 155–166. 8 indexed citations

18.

Robson, Matthew J., Meenal Elliott, Michael J. Seminerio, & Rae R. Matsumoto. (2011). Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo. European Neuropsychopharmacology. 22(4). 308–317. 68 indexed citations

19.

Seminerio, Michael J., Nidhi Kaushal, Jamaluddin Shaikh, et al.. (2010). Sigma (σ) receptor ligand, AC927 (N-phenethylpiperidine oxalate), attenuates methamphetamine-induced hyperthermia and serotonin damage in mice. Pharmacology Biochemistry and Behavior. 98(1). 12–20. 21 indexed citations

20.

Stavitskaya, Lidiya, et al.. (2010). The effect of the pyridyl nitrogen position in pyridylpiperazine sigma ligands. Bioorganic & Medicinal Chemistry Letters. 20(8). 2564–2565. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact